Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. Issue 6 (2nd June 2016)

• Record Type: Journal Article
• Authors: Ye, Xing-Nong; Zhou, Xin-Ping; Wei, Ju-Ying; Xu, Gai-Xiang; Li, Ying; Mao, Li-Ping; Huang, Jian; Ren, Yan-Ling; Mei, Chen; Wang, Jing-Han; Lou, Yin-Jun; Ma, Li-Ya; Yu, Wen-Juan; Ye, Li; Xie, Li-Li; Luo, Yin-Wan; Hu, Chao; Niu, Lin-Mei; Dou, Min-Hua; Jin, Jie; Tong, Hong-Yan
• Is Part Of: Leukemia & lymphoma. Volume 57:Issue 6(2016:Jun.)
• Page Start: 1311
• Page End: 1318
• Publication Date: 2016-06-02
• Subjects: Acute myeloid leukemia -- cytarabine -- decitabine -- idarubicin -- myelodysplastic syndrome; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2015.1091931
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Decitabine (DAC) is commonly used for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Previous studies have indicated DAC sequentially combined with idarubicin was an effective treatment for myeloid neoplasms. Therefore, a clinical study was conducted of the sequential combination of DAC followed by low-dose idarubicin/cytarabine in high-risk myeloid neoplasms. A total of 30 patients with a diagnosis of high-risk MDS, AML evolving from MDS or relapsed/refractory AML were enrolled in the study. DAC was administered 20 mg/m 2 daily for 3 consecutive days. Idarubicin (3 mg/m 2 /day) was administered 24 h after the last administration of DAC for 5–7 consecutive days, combined with cytarabine (30 mg/m 2 /day) for 7–14 days. The overall complete remission rate was 66.67%. The results demonstrate that epigenetic priming with decitabine followed by low-dose idarubicin/ytarabine has an increased anti-leukemia effect compared to traditional chemotherapy in high-risk myeloid neoplasms.